These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34209360)

  • 1. High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Sikic D; Taubert H; Wirtz RM; Breyer J; Eckstein M; Weyerer V; Kubon J; Erben P; Bolenz C; Burger M; Hartmann A; Wullich B; Wach S; Keck B
    Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34209360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.
    Sikic D; Breyer J; Hartmann A; Burger M; Erben P; Denzinger S; Eckstein M; Stöhr R; Wach S; Wullich B; Keck B; Wirtz RM; Otto W
    Transl Oncol; 2017 Jun; 10(3):340-345. PubMed ID: 28342317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.
    Sikic D; Taubert H; Breyer J; Eckstein M; Weyerer V; Keck B; Kubon J; Otto W; Worst TS; Kriegmair MC; Erben P; Hartmann A; Wullich B; Wirtz RM; Wach S
    Cancer Manag Res; 2021; 13():6567-6578. PubMed ID: 34447272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y
    BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA-Expression of
    Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Sikic D; Eckstein M; Wirtz RM; Jarczyk J; Worst TS; Porubsky S; Keck B; Kunath F; Weyerer V; Breyer J; Otto W; Rinaldetti S; Bolenz C; Hartmann A; Wullich B; Erben P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
    Sikic D; Eckstein M; Weyerer V; Kubon J; Breyer J; Roghmann F; Kunath F; Keck B; Erben P; Hartmann A; Wirtz RM; Wullich B; Taubert H; Wach S
    Urol Oncol; 2022 Feb; 40(2):63.e9-63.e18. PubMed ID: 34330652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.
    Erben P; Sikic D; Wirtz RM; Martini T; Weis CA; Breyer J; Otto W; Keck B; Hartmann A; Bolenz C;
    Virchows Arch; 2019 Feb; 474(2):209-217. PubMed ID: 30483954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
    Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
    J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor Predicts First and Multiple Recurrences in Non-Muscle Invasive Urothelial Carcinoma of the Bladder.
    Yonekura S; Terauchi F; Hoshi K; Yamaguchi T; Kawai S
    Pathol Oncol Res; 2019 Jul; 25(3):987-994. PubMed ID: 29862474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.
    Sikic D; Wirtz RM; Wach S; Dyrskjøt L; Erben P; Bolenz C; Breyer J; Otto W; Hoadley KA; Lerner SP; Eckstein M; Hartmann A; Keck B
    Transl Oncol; 2019 Apr; 12(4):661-668. PubMed ID: 30831560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients.
    Shang Z; Wang J; Wang X; Yan H; Cui B; Jia C; Wang Q; Cui X; Li J; Ou T
    Cancer Manag Res; 2018; 10():1177-1190. PubMed ID: 29795989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis.
    Kubon J; Sikic D; Eckstein M; Weyerer V; Stöhr R; Neumann A; Keck B; Wullich B; Hartmann A; Wirtz RM; Taubert H; Wach S
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer.
    Wahby S; Jarczyk J; Fierek A; Heinkele J; Weis CA; Eckstein M; Martini T; Porubsky S; Hafner M; Erben P
    Transl Oncol; 2021 Jan; 14(1):100900. PubMed ID: 33099185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Nonmuscle-Invasive Bladder Cancer Treated with GreenLight Laser Vaporization.
    Luo F; Ma C; Wu J; Li J
    Photobiomodul Photomed Laser Surg; 2019 May; 37(5):312-317. PubMed ID: 31084565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.